Press coverage about Jounce Therapeutics (NASDAQ:JNCE) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jounce Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.537051550136 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Jounce Therapeutics (JNCE) traded up 0.40% on Monday, reaching $12.53. 115,168 shares of the company traded hands. Jounce Therapeutics has a 52-week low of $12.32 and a 52-week high of $29.29. The stock has a 50-day moving average of $14.55 and a 200 day moving average of $20.05. The company’s market capitalization is $402.64 million.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.07. The company had revenue of $20.30 million during the quarter, compared to the consensus estimate of $19.71 million. Jounce Therapeutics’s revenue for the quarter was up 202900.0% on a year-over-year basis. On average, equities analysts forecast that Jounce Therapeutics will post ($0.65) EPS for the current year.

Several research analysts recently weighed in on JNCE shares. Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Wednesday, April 26th. Cowen and Company restated a “buy” rating on shares of Jounce Therapeutics in a research report on Thursday, April 20th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $28.67.

COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at

About Jounce Therapeutics

Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with's FREE daily email newsletter.